Tau PET Imaging With 18F-T807(AV1451) in Neurodegenerative Disorders
Study Details
Study Description
Brief Summary
Alzheimer's disease, Parkinson's disease, and Huntington's disease are common neurodegenerative diseases. Tau is a microtubule-associated protein, and aggregated tau resulting from hyperphosphorylation is a pathological feature of a group of neurodegenerative diseases known as tauopathies. The 18F-T807 (AV1451) molecular probe is a novel molecularly targeted imaging agent that exhibits high affinity and good selectivity for tau.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Early Phase 1 |
Detailed Description
In this study, 18F-T807 (AV1451) molecular probe PET/CT was used to monitor the regional distribution and the degree of deposition in patients with neurodegenerative diseases, and compared with clinical symptoms to evaluate its value in the early differential diagnosis of neurodegenerative diseases.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: 18F-T807, PET/CT PET/CT perform after injecting 18F-T807 |
Drug: 18F-T807
Intravenous injection of one dose of 10mCi (370MBq, ±5%) 18F-T807. Each subject receive a single intravenous injection of 18F-T807, and undergo PET/CT imaging within the specificed time.
|
Outcome Measures
Primary Outcome Measures
- standardized uptake value ratio (SUVR) [From right after tracer injection to 2-hours post-injection]
the ratio of radioactivity in a cerebral region to that in the cerebellum as a reference
- Aβ42 in CSF [Within 2 hours prior to tracer injection]
Aβ42 (amyloid beta isoform 42) is significantly lower in the cerebrospinal fluid of patients with neurodegenerative diseases and is one of the biomarkers used clinically to diagnose neurodegenerative diseases
- t-tau in CSF [Within 2 hours prior to tracer injection]
t-tau (total tau) is significantly increased in the cerebrospinal fluid of patients with neurodegeneration and is one of the biomarkers used clinically to diagnose neurodegeneration
- p-tau in CSF [Within 2 hours prior to tracer injection]
p-tau (tau phosphorylated at Thr-181) is significantly increased in the cerebrospinal fluid of patients with neurodegeneration and is one of the biomarkers used clinically to diagnose neurodegeneration
- NfL in CSF [Within 2 hours prior to tracer injection]
NfL (neurofilament light chain) is significantly increased in the cerebrospinal fluid of patients with neurodegeneration and is one of the biomarkers used clinically to diagnose neurodegeneration
- NfL in the blood [Within 2 hours prior to tracer injection]
NfL is significantly increased in the blood of patients with neurodegeneration and is one of the biomarkers used clinically to diagnose neurodegeneration
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients or their families complain of significant memory impairment;
-
Objective memory impairment (e.g., tests of article identification, recall, delayed memory);
-
Be able to obtain complete diagnosis and treatment records and be able to carry out long-term follow-up;
-
Signed written consent.
Exclusion Criteria:
-
Psychiatric disorders: including anxiety disorder, affective disorder, severe psychosis, or drug-induced psychosis;
-
Pregnancy or lactation.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University | Fuzhou | Fujian | China | 350005 |
Sponsors and Collaborators
- First Affiliated Hospital of Fujian Medical University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- MRCTA, ECFAH of FMU [2021]129